Tag: Abbott Vascular

Xience Sierra is now on European market

The CE mark has been awarded to a new-generation of Abbott Vascular's everolimus-eluting, metallic stent Xience. The Xience Sierra, according to a press release,...

“Low commercial sales” prompt Abbott to pull the plug on selling...

Abbott has announced that it is to stop selling its first-generation bioresorbable vascular scaffold (Absorb, Abbott Vascular) because of poor sales. The announcement follows...

New study to evaluate safety of three-month DAPT with Xience in...

A new study, XIENCE Short DAPT, will evaluate whether three months of dual antiplatelet therapy (DAPT) is non-inferior to the standard duration of DAPT...

EuroPCR 2017: Study finds no association between implantation technique and risk...

A study—AIDA (Amsterdam investigator-initiated Absorb strategy all-comers trial)—presented at EuroPCR  (16–19 May, Paris, France) and published in The New England Journal of Medicine has...

Absorb GTS to be restricted to registry use only in Europe

Abbott Vascular has written a letter to European physicians to say that from 31 May, its bioresorbable vascular scaffold (Absorb) will only be available...

ACC 2017: Two-year rate of target lesion failure significantly higher with...

Two-year data from the ABSORB III study indicate that a bioresorbable vascular scaffold (Absorb, Abbott Vascular) is associated with a significantly higher rate of...

The implications of ABSORB II three-year results for the future of...

The idea of a fully bioresorbable scaffold is attractive as the need for mechanical support for the healing artery after percutaneous coronary intervention (PCI)...

Combining MitraClip mitral valve repair with left atrial appendage occlusion is...

Shingo Kuwata (University Heart Center, Zurich, Switzerland) and others report in Eurointervention that atrial fibrillation is a “frequent comorbidity” in patients with mitral regurgitation...

St Jude Medical shareholders approve merger with Abbott

St Jude Medical has announced that, based on the preliminary voting results from St Jude Medical’s Annual Meeting of Shareholders held on 26 October, St...

PCRLV 2016: MitraClip may be “safe and feasible” for treating tricuspid...

A first-in-man study indicates that percutaneous edge-to-edge repair with Abbott Vascular’s MitraClip system is a safe and feasible treatment for tricuspid regurgitation. According to...